Jobs / United States / Glaxosmithkline LLC
Director, Oncology Early Translational Biomarkers
Glaxosmithkline LLC · 🇺🇸 USA - Massachusetts - Waltham
Sponsorship verdict
Sponsorship possible
One solid signal, not two — worth applying, and worth asking about sponsorship early.
- Employer is on a government sponsor recordThe US Department of Labor certified 39 H-1B/E-3 labor condition applications for this employer between Oct 2025 and Jun 2026 (latest Jun 2026) — the step every H-1B hire needs first. USCIS also records 15 H-1B approvals in FY2023. Source: LCA disclosure data (US Department of Labor (OFLC)).
- The posting doesn’t mention sponsorshipSilence isn’t a refusal — ask the recruiter before investing much time.
- No salary bar for this routeH-1B has no fixed salary bar: the employer must pay at least the prevailing wage for the role and area. Cap-subject employers enter a lottery weighted by wage level. Source: https://www.federalregister.gov/documents/2025/12/29/2025-23853/weighted-selection-process-for-registrants-and-petitioners-seeking-to-file-cap-subject-h-1b, rules effective 2026-02-27.
- What Glaxosmithkline LLC paid sponsored hires in similar roles1 certified filing for “Associate Director - Global Regulatory Affairs, Oncology” (Regulatory Affairs Managers) in WA: $154k–$154k, median $154k. Most were filed at wage level II (100%) — 2 lottery entries, ≈31% projected selection odds for cap-subject employers. Source: US Department of Labor LCA disclosure data (Oct 2025 – Jun 2026).
- Confirmed live todayWhen a source last listed this job as open.
US H-1B: cap-subject employers enter a lottery weighted by wage level — Level I gets 1 entry, Level IV gets 4 (DHS projected selection odds ≈15% at Level I to ≈61% at Level IV). Universities and non-profit research employers are cap-exempt. The $100,000 fee for new petitions from abroad is currently blocked by a court order (appeal pending).
A verdict summarises public evidence; it is not legal advice and never a guarantee — the employer and the immigration authority decide. Sign in to factor in where you can already work.
Or apply yourself on the official page →
Sponsor Radar — Glaxosmithkline LLC
The US Department of Labor certified 39 H-1B/E-3 labor condition applications for this employer between Oct 2025 and Jun 2026 (latest Jun 2026) — the step every H-1B hire needs first. USCIS also records 15 H-1B approvals in FY2023. Source: LCA disclosure data (US Department of Labor (OFLC)).
Past sponsorship or register membership never guarantees sponsorship for this vacancy or for you. Full Sponsor Radar for Glaxosmithkline LLC →
About the role
Business Introduction At GSK, we have bold ambitions for patients, aiming to positively impact the health of 2.5 billion people by the end of the decade. Our R&D focuses on discovering and delivering vaccines and medicines, combining our understanding of the immune system with cutting-edge technology to transform people’s lives. GSK fosters a culture ambitious for patients, accountable for impact, and committed to doing the right thing, making sure that we focus our efforts on accelerating significant assets that meet patients’ needs and have the highest probability of success. We’re uniting science, technology, and talent to get ahead of disease together. Find out more: Our approach to R&D For candidates seeking to be located at our Stevenage site, this role will temporarily be based at Stevenage. However, the Company plans to relocate its offices to Cambridge, UK. The location of this role will therefore subsequently change to Cambridge, UK in accordance with timelines to be set by the Company. The relocation is currently proposed to take effect by early 2029. Director, Oncology Early Translational Biomarkers Are you an experienced leader in Oncology Translational Medicine (OTM) looking to be part of an innovative, dynamic and growing organization? Do you thrive at the intersection of biomarker strategy, early clinical development and mechanistic research across multiple therapeutic modalities? If so, this Director, Oncology Early Translational Biomarkers is an exciting opportunity to explore. GSK Oncology has a rapidly growing and diverse pipeline spanning novel small molecules, first- and best-in-class large molecules, and cutting-edge therapies, the opportunity to shape translational strategy across our early Oncology programs represents a rare and exciting career opportunity. You will partner with world-class scientists, clinicians, and KOLs—making decisions that directly impact patients with cancer. Job Purpose: The Director , Oncology Early Translational Biomarkers is accountable for the definition and implementation of a translational biomarker strategy and delivery across a expanding early oncology portfolio of spanning both small and large molecules, novel modalities and immune cell engagers. The Early Translational Biomarkers team provides end-to-end translational medicine support from development and integration of biomarker strategies, assay development and technical validation through clinical deployment and data interpretation across early-phase proof of concept studies. You will be the scientific and operational owner of translational medicine strategy for the early Oncology portfolio, embedded as the dedicated translational lead across program teams. You will deliver biomarker and translational strategies from preclinical through Phase 1. The role covers a wide range of therapeutic modalities requiring deep disease biology expertise, versatile biomarker and assay knowledge alongside experience in clinical implementation. The role partners closely with Oncology Research Unit, Discovery, Innovative Biological Model Systems, Clinical Development and Oncology Tumour teams, Clinical Operations, Diagnostics, Biomarker Operations and external partners to ensure translational readiness, de-risk clinical entry and accelerate go/no-go decisions. Key Responsibilities: • Act as the translational medicine lead for assigned early Oncology programs (preclinical to Phase 1): define and own biomarker and translational strategies, plans and decision-enabling datasets. • Identify cutting edge science and technological advances and incorporate them into biomarker strategies to guide indication selection, patient enrichment, and combination strategies. • Develop program-specific translational plans including hypothesis-dri